{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:53:42Z","timestamp":1780926822819,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.expneurol.2010.07.018","type":"journal-article","created":{"date-parts":[[2010,7,25]],"date-time":"2010-07-25T08:53:20Z","timestamp":1280048000000},"page":"408-415","source":"Crossref","is-referenced-by-count":30,"title":["Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias"],"prefix":"10.1016","volume":"225","author":[{"given":"Torun","family":"Malml\u00f6f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniella","family":"Rylander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf-Giesbert","family":"Alken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torgny H.","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Angela","family":"Cenci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Schilstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2010.07.018_bb0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.expneurol.2004.11.013","article-title":"Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates","volume":"192","author":"Bibbiani","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0010","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/jps.2600640306","article-title":"Studies with deuterated drugs","volume":"64","author":"Blake","year":"1975","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0015","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0022-3565(25)24503-7","article-title":"Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys","volume":"272","author":"Blanchet","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0020","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1471-4159.2006.04124.x","article-title":"Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia","volume":"99","author":"Cenci","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/0471142301.ns0925s41","article-title":"Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice","volume":"25","author":"Cenci","year":"2007","journal-title":"Curr. Protoc. Neurosci."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0030","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/nrn877","article-title":"Animal models of neurological deficits: how relevant is the rat?","volume":"3","author":"Cenci","year":"2002","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0035","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00075197-200309000-00004","article-title":"Measuring in vivo metabolism using heavy water","volume":"6","author":"Dufner","year":"2003","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"10.1016\/j.expneurol.2010.07.018_bb0040","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of Parkinson's disease","volume":"351","author":"Fahn","year":"2004","journal-title":"N Engl J. Med."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0045","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nn1103","article-title":"Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission","volume":"6","author":"Floresco","year":"2003","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0050","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1476-5381.1986.tb10179.x","article-title":"Selective inhibition of monoamine oxidase type B by MDL 72145 increases the central effects of L-dopa without modifying its cardiovascular effects","volume":"87","author":"Fozard","year":"1986","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0055","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/mds.20464","article-title":"Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004","volume":"20","author":"Goetz","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0060","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0091-3057(81)90342-7","article-title":"Potentiation by deprenil of 1-dopa induced circling in nigral-lesioned rats","volume":"15","author":"Heikkila","year":"1981","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0065","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1042\/cs0800277","article-title":"Stable isotopes in clinical research: safety reaffirmed","volume":"80","author":"Jones","year":"1991","journal-title":"Clin. Sci. (Lond)"},{"key":"10.1016\/j.expneurol.2010.07.018_bb0070","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/j.1552-4604.1986.tb03544.x","article-title":"Stable isotopes: origins and safety","volume":"26","author":"Klein","year":"1986","journal-title":"J. Clin. Pharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.expneurol.2010.07.018_bb0075","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1007\/PL00014267","article-title":"Safety of stable isotope use","volume":"156","author":"Koletzko","year":"1997","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0080","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1139\/y99-005","article-title":"Pharmacological uses and perspectives of heavy water and deuterated compounds","volume":"77","author":"Kushner","year":"1999","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0085","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbr.2006.09.019","article-title":"The \u201cmotor complication syndrome\u201d in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration","volume":"177","author":"Lindgren","year":"2007","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0090","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0095","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1046\/j.1471-4159.2003.01632.x","article-title":"Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia","volume":"84","author":"Lundblad","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0100","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.expneurol.2008.05.003","article-title":"Altered behavioural and neurochemical profile of L-DOPA following deuterium substitutions in the molecule","volume":"212","author":"Malml\u00f6f","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0105","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.expneurol.2005.11.002","article-title":"Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time?","volume":"197","author":"Marin","year":"2006","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0110","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1021\/bi00282a011","article-title":"Magnitude of intrinsic isotope effects in the dopamine beta-monooxygenase reaction","volume":"22","author":"Miller","year":"1983","journal-title":"Biochemistry"},{"key":"10.1016\/j.expneurol.2010.07.018_bb0115","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuropharm.2004.02.016","article-title":"Rasagiline enhances L-DOPA-induced contralateral turning in the unilateral 6-hydroxydopamine-lesioned guinea-pig","volume":"47","author":"Moses","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2010.07.018_bb0120","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1353-8020(01)00024-4","article-title":"Motor fluctuations and dyskinesia in Parkinson's disease","volume":"8","author":"Nutt","year":"2001","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0125","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1474-4422(06)70521-X","article-title":"Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications","volume":"5","author":"Olanow","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0130","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.0b013e3181a1d44c","article-title":"The scientific and clinical basis for the treatment of Parkinson disease (2009)","volume":"72","author":"Olanow","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2010.07.018_bb0135","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nn1040","article-title":"Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia","volume":"6","author":"Picconi","year":"2003","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0140","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1124\/jpet.108.150425","article-title":"Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling","volume":"330","author":"Rylander","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0145","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/458269a","article-title":"Big interest in heavy drugs","volume":"458","author":"Sanderson","year":"2009","journal-title":"Nature"},{"issue":"Pt 11","key":"10.1016\/j.expneurol.2010.07.018_bb0150","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1093\/brain\/123.11.2297","article-title":"Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study","volume":"123","author":"Schrag","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2010.07.018_bb0155","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.parkreldis.2006.07.002","article-title":"Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade)","volume":"12","author":"Sharma","year":"2006","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0160","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1468-1331.2008.02106.x","article-title":"Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight","volume":"15","author":"Sharma","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0165","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.nbd.2003.11.025","article-title":"Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy)","volume":"15","author":"Stefanova","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0170","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/mds.870130222","article-title":"Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease","volume":"13","author":"Syed","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0175","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/nbdi.2002.0499","article-title":"L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function","volume":"10","author":"Winkler","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0180","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/0006-2952(86)90094-8","article-title":"Stereospecific deuterium substitution at the alpha-carbon position of dopamine and its effect on oxidative deamination catalyzed by MAO-A and MAO-B from different tissues","volume":"35","author":"Yu","year":"1986","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.expneurol.2010.07.018_bb0185","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1016\/0006-2952(82)90601-3","article-title":"Deuterium isotope effect on the enzymatic oxidation of dopamine and serotonin","volume":"31","author":"Yu","year":"1982","journal-title":"Biochem. Pharmacol."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488610002566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488610002566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T09:58:54Z","timestamp":1740304734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488610002566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0014488610002566"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2010.07.018","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}